Health Care Technology
Company Overview of CollabRx, Inc.
As of November 2, 2015, CollabRx, Inc. was acquired by Medytox Solutions, Inc., in a reverse merger transaction. CollabRx, Inc. provides cloud-based expert systems to inform healthcare decision-making in the United States and internationally. The company develops and markets medical information and clinical decision support products and services. It offers Genetic Variant Annotation Service, which provides the clinical interpretation of genetic variants in human tumor biopsies; Therapy Finders, a series of cancer-specific Web-based apps that are accessed by physicians and patients; and CancerRx, a mobile app with reference tools, social media, and expert systems. The company’s cloud-based ex...
44 Montgomery Street
San Francisco, CA 94104
Founded in 1972
Key Executives for CollabRx, Inc.
CollabRx, Inc. does not have any Key Executives recorded.
CollabRx, Inc. Key Developments
CollabRx Approves an Amendment to Certificate of Incorporation
Oct 30 15
CollabRx, Inc., at its special stockholders meeting held on October 30, 2015, approved an amendment to the CollabRx certificate of incorporation, as amended, to effect a reverse split of CollabRx's common stock at a specific ratio from 1-for-2.5 to 1-for-10, to be effected immediately prior to the effective time of the merger.
CollabRx, Inc., Special/Extraordinary Shareholders Meeting, Oct 30, 2015
Sep 24 15
CollabRx, Inc., Special/Extraordinary Shareholders Meeting, Oct 30, 2015., at 10:30 Pacific Standard Time. Location: CollabRx's offices located at 44 Montgomery Street. Agenda: To consider and act on several proposals recommended by CollabRx board and management.
CollabRx Announces Receipt Of NASDAQ Notice Of Noncompliance For Bid Price
Jun 5 15
CollabRx, Inc. announced that it received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on The Nasdaq Capital Market under the symbol "CLRX." CollabRx has been provided a grace period of 180-calendar days, or until November 30, 2015, to regain compliance with the minimum bid price requirement. If at any time during the 180-day grace period, the minimum closing bid price per share of the Company's common stock closes at or above $1.00 for a minimum of ten consecutive business
days (the Nasdaq Staff has the discretion to monitor the stock price for up to 20 trading days), CLRX will regain compliance and the matter will be closed. In the event the Company does not regain compliance within this grace period, it may be eligible to receive an additional 180-day grace period, provided that CLRX meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period by effecting a reverse stock split, if necessary. In the event the Company is not able to regain compliance by the end of the applicable grace period, the Company's securities would be subject to delisting unless the Company requested a hearing before the Nasdaq Listing Qualifications Panel. CollabRx management intends to monitor the stock price and is considering available actions that could be taken to regain compliance if the stock price remains below the $1.00 per share requirement at the end of the applicable grace period.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 22, 2015